Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ingested (oral) adrenocorticotropic hormone (ACTH) inhibits interleukin-17 in the central nervous system after adoptive transfer of T helper (Th)1/Th17 T cells in the mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis.

Journal of the neurological sciences·2023
Same author

The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica.

Autoimmunity reviews·2022
Same author

Ingested (Oral) Adrenocorticotropic Hormone Inhibits IL-17 in the Central Nervous System in the Mouse Model of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.

ImmunoHorizons·2022
Same author

Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer's Disease.

Journal of Alzheimer's disease : JAD·2021
Same author

A proposal: How to study pro-myelinating proteins in MS.

Autoimmunity reviews·2021
Same author

Immune reconstitution therapy in NMOSD.

Multiple sclerosis and related disorders·2021
Same journal

The multifaceted role of acetamide derivative of chalcone: Anti-inflammatory action and impact on osteoclastogenesis, insights on NF-κB and MAPK pathway.

Cytokine·2026
Same journal

Icariin alleviates ovariectomy-induced osteoporosis by promoting M2 macrophage polarization and suppressing osteoclast activation.

Cytokine·2026
Same journal

Single-cell profiling of the immune landscape at the maternal-fetal interface in unexplained recurrent miscarriage.

Cytokine·2026
Same journal

EGFR as a context-dependent modulator of endothelial inflammation: A systematic review.

Cytokine·2026
Same journal

Harnessing the Power of IL-12: Revolutionizing Cancer Therapy with Combinatorial Strategies.

Cytokine·2026
Same journal

Corrigendum to "CCL17 and CCL19 are markers of disease progression in alveolar echinococcosis" [Cytokine 181 (2024) 156669].

Cytokine·2026
See all related articles

Related Experiment Video

Updated: Mar 1, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K

Ingested (oral) rituximab inhibits EAE.

Staley A Brod1

  • 1Department of Neurology, Medical College of Wisconsin, Froedtert West Clinic, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226, United States.

Cytokine
|July 4, 2016
PubMed
Summary
This summary is machine-generated.

Orally administered rituximab (RTX) effectively inhibited ongoing autoimmune disease and central nervous system inflammation in a mouse model. This oral RTX treatment reduced pro-inflammatory cytokines without increasing anti-inflammatory ones.

Keywords:
Adoptive transferAntibodyEAEOral proteinsRituximab

More Related Videos

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.5K
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

8.3K

Related Experiment Videos

Last Updated: Mar 1, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.5K
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

8.3K

Area of Science:

  • Immunology
  • Neuroscience
  • Pharmacology

Background:

  • Blocking CD20 shows promise in treating autoimmune diseases like multiple sclerosis (MS) and rheumatoid arthritis (RA).
  • Rituximab (RTX) is a clinically used anti-CD20 antibody with established roles in oncology and autoimmune conditions.

Purpose of the Study:

  • To investigate the anti-inflammatory effects of orally administered RTX in an experimental autoimmune encephalomyelitis (EAE) model.
  • To determine if oral RTX administration could replicate the therapeutic benefits seen with other administration routes.

Main Methods:

  • Mice were induced with EAE using MOG peptide 35-55 and treated with oral RTX or saline during active disease.
  • Immune cells from RTX-treated mice were adoptively transferred to recipient mice to assess protective effects.
  • Disease progression, central nervous system (CNS) inflammation, and cytokine profiles were analyzed.

Main Results:

  • Oral RTX administration significantly inhibited ongoing EAE and reduced inflammation.
  • Adoptive transfer of cells from RTX-treated donors conferred protection against EAE induction and decreased inflammation.
  • A notable decrease in pro-inflammatory cytokines (IFN-γ, IL-12, IL-17, TNF-α) was observed without compensatory increases in anti-inflammatory cytokines.

Conclusions:

  • Orally administered RTX demonstrates efficacy in inhibiting autoimmune disease and CNS inflammation.
  • The study suggests a potential for oral RTX as a therapeutic strategy for autoimmune conditions.
  • Oral RTX effectively modulates pro-inflammatory cytokine responses without disrupting immune balance.